Home › Compare › CAFS vs JNJ

CAFS vs JNJ: Dividend Comparison 2026

CAFS yields 40816.33% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CAFS wins by $6.335337413603696e+22M in total portfolio value
10 years
CAFS
CAFS
● Live price
40816.33%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.335337413603696e+22M
Annual income
$63,049,505,730,141,920,000,000,000,000.00
Full CAFS calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — CAFS vs JNJ

📍 CAFS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCAFSJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CAFS + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CAFS pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CAFS
Annual income on $10K today (after 15% tax)
$3,469,387.76/yr
After 10yr DRIP, annual income (after tax)
$53,592,079,870,620,625,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, CAFS beats the other by $53,592,079,870,620,625,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CAFS + JNJ for your $10,000?

CAFS: 50%JNJ: 50%
100% JNJ50/50100% CAFS
Portfolio after 10yr
$3.167668706801848e+22M
Annual income
$31,524,752,865,070,960,000,000,000,000.00/yr
Blended yield
99.52%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CAFS
No analyst data
Altman Z
-10.5
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CAFS buys
0
JNJ buys
0
No recent congressional trades found for CAFS or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCAFSJNJ
Forward yield40816.33% ✓3.36%
Annual dividend / share$2.00$4.96 ✓
Payout ratio50% ✓55%
1-year div growth0%4.2% ✓
5-year div CAGR0%5.8% ✓
Portfolio after 10y$6.335337413603696e+22M$20.0K ✓
Annual income after 10y$63,049,505,730,141,920,000,000,000,000.00 ✓$827.78
Total dividends collected$6.333341125941146e+22M ✓$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CAFS vs JNJ ($10,000, DRIP)

YearCAFS PortfolioCAFS Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$4,092,333$4,081,632.65$10,676$355.77+$4.08M → CAFS
2$1,565,444,084$1,561,065,288.22$11,407$389.39+$1565.43M → CAFS
3$559,764,612,945$558,089,587,774.68$12,198$426.53+$559764.60M → CAFS
4$187,102,893,076,834$186,503,944,940,983.20$13,056$467.62+$187102893.06M → CAFS
5$58,461,384,295,003,140$58,261,184,199,410,920.00$13,987$513.12+$58461384294.99M → CAFS
6$17,075,679,818,265,373,000$17,013,126,137,069,720,000.00$14,998$563.56+$17075679818265.36M → CAFS
7$4,662,453,207,316,437,700,000$4,644,182,229,910,893,400,000.00$16,098$619.52+$4662453207316438.00M → CAFS
8$1,190,107,817,342,153,000,000,000$1,185,118,992,410,324,500,000,000.00$17,295$681.69+$1190107817342152960.00M → CAFS
9$283,989,164,387,886,140,000,000,000$282,715,749,023,330,050,000,000,000.00$18,599$750.82+$283989164387886137344.00M → CAFS
10$63,353,374,136,036,960,000,000,000,000$63,049,505,730,141,920,000,000,000,000.00$20,022$827.78+$6.335337413603696e+22M → CAFS

CAFS vs JNJ: Complete Analysis 2026

CAFS — Stock

Café Serendipity Holdings, Inc., a development stage company, focuses on building upscale turnkey franchises to the recreational and medical marijuana industry in the United States. It intends to market a product line of accessories, apparel, coffee and teas, bakery and other edibles, lotions, marijuana, and oils through a coast to coast franchise and dealer network to the recreational and the approximately 6,000 existing legal medical marijuana dispensaries. The company is based in Newport Beach, California.

Full CAFS Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this CAFS vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CAFS vs SCHDCAFS vs JEPICAFS vs OCAFS vs KOCAFS vs MAINCAFS vs ABBVCAFS vs MRKCAFS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.